KLINIQ raises 2026 target after strong H1, brokers see more upside
Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.
This is the core new event that resets growth expectations for the year.
Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.
Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.
Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.
Dividend news is a new, concrete return of cash to shareholders that supports the price.
Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.
It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.